Earendil Labs Secures Exclusive WuXi XDC Payload-Linker Platform in $885 Million ADC Partnership

New updates have been reported about Earendil Labs.

Earendil Labs has entered a wide-ranging strategic collaboration with WuXi XDC that positions the AI-driven biotech at the center of next-generation antibody-drug conjugate development by combining its machine-learning antibody discovery with WuXi XDC’s WuXiTecan-2 payload-linker technology. Under the agreement, Earendil Labs receives an exclusive global license to use WuXiTecan-2 against multiple specified targets, anchoring its pipeline of antibodies and bispecifics to a clinically validated ADC platform and creating a clear route from discovery through commercialization.

The deal carries potential value of up to approximately $885 million for WuXi XDC, including an upfront payment and development, regulatory, and commercial milestones, while WuXi XDC will also earn tiered royalties on future net sales of any approved ADC products. Operationally, WuXi XDC will handle CMC development and manufacturing of ADC components through its integrated CRDMO network, allowing Earendil Labs to concentrate capital and management focus on late-stage product development, global regulatory filings, and commercialization strategy.

Earendil CEO Jian Peng characterized the alliance as a pivotal step in using AI to compress biopharma R&D timelines, citing WuXi XDC’s end-to-end capabilities as a force multiplier for the company’s discovery engine. President and co-CEO Zhenping Zhu highlighted that the addition of WuXiTecan-2 is expected to raise the probability of technical success and accelerate the progression of Earendil’s bispecific and multispecific ADC pipeline, particularly in oncology and autoimmune indications.

Strategically, the partnership deepens Earendil Labs’ access to scaled manufacturing and de-risks key aspects of ADC development, while preserving upside through exclusive rights on selected targets and future global commercialization. For investors and partners, the collaboration signals Earendil’s intent to transition from a primarily R&D-focused AI biologics player to a fully integrated therapeutics company with a clearer path to revenue as ADC candidates advance toward the clinic and potential launch.